297 related articles for article (PubMed ID: 21748365)
1. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
Hirano T; Ohguro N; Hohki S; Hagihara K; Shima Y; Narazaki M; Ogata A; Yoshizaki K; Kumanogoh A; Kishimoto T; Tanaka T
Mod Rheumatol; 2012 Apr; 22(2):298-302. PubMed ID: 21748365
[TBL] [Abstract][Full Text] [Related]
2. A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.
Chen J; Chen S; He J
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):116-118. PubMed ID: 28980896
[TBL] [Abstract][Full Text] [Related]
3. Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases.
Diamantopoulos AP; Hatemi G
Rheumatology (Oxford); 2013 Oct; 52(10):1923-4. PubMed ID: 23559575
[No Abstract] [Full Text] [Related]
4. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
[TBL] [Abstract][Full Text] [Related]
5. Refractory neuro-Behçet treated by tocilizumab: a case report.
Urbaniak P; Hasler P; Kretzschmar S
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
[TBL] [Abstract][Full Text] [Related]
6. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
[TBL] [Abstract][Full Text] [Related]
9. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
11. Visual prognosis in patients with Behçet's disease receiving colchicine, systemic corticosteroid or cyclosporin.
Hayasaka S; Kawamoto K; Noda S; Kodama T
Ophthalmologica; 1994; 208(4):210-3. PubMed ID: 7970549
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
13. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
Lockwood CM; Hale G; Waldman H; Jayne DR
Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
[TBL] [Abstract][Full Text] [Related]
14. Infliximab in refractory uveitis due to Behçet's disease.
Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of tocilizumab in Behcet's disease: A systematic literature review.
Akiyama M; Kaneko Y; Takeuchi T
Semin Arthritis Rheum; 2020 Aug; 50(4):797-804. PubMed ID: 32544751
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
[No Abstract] [Full Text] [Related]
17. [A case report of malignant lymphoma receiving infliximab therapy with Behçet's disease].
Sonoda KH; Fukuhara T; Yoshikawa H; Takeda A; Yoshimura T; Akahoshi M; Kusumoto H; Kohno K; Kato K; Akashi K; Kohashi K; Aijima S; Namba K; Ishibashi T
Nippon Ganka Gakkai Zasshi; 2014 May; 118(5):440-5. PubMed ID: 25011243
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review.
Deroux A; Chiquet C; Bouillet L
Semin Arthritis Rheum; 2016 Jun; 45(6):733-7. PubMed ID: 26743073
[TBL] [Abstract][Full Text] [Related]
19. Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm.
Terreaux W; Mestrallet S; Fauconier M; Pennaforte JL; Penalba C; Eschard JP; Salmon JH
Rheumatology (Oxford); 2015 Nov; 54(11):2111-3. PubMed ID: 26175469
[No Abstract] [Full Text] [Related]
20. Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab.
Cantarini L; Lopalco G; Vitale A; Coladonato L; Rigante D; Lucherini OM; Lapadula G; Iannone F
Clin Rheumatol; 2015 Jun; 34(6):1141-3. PubMed ID: 24733249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
